LUGPA Annual Meeting

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.

The PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.

"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD.

"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.

Specifically, Jayram highlights pembrolizumab, nadofaragene firadenovec-vncg, and N-803 (Anktiva).

“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes they don't,” says Thomas Mueller, MD.

"It's actually a very exciting time to be a robotic surgeon," says Ronney Abaza, MD, FACS.

“It's really a reapplication of the existing technology for BPH that is familiar to many of us already and we use in our clinical practices,” says Arvin K. George, MD.

"[A parental leave policy] is something that this generation, both men and women, not only are going to be happy to see, they're going to expect it," says Kari Bailey, MD.

“Opportunity wise, I always say that if you don't perform the test, then you're limiting treatment options for your patients,” says Kara Cossis, PA-C, MPH.

“When a patient knows that there are so many tools that are there for people, it gives them hope. It gives their caregivers hope,” says Joy Maulik, CRNP.

"It's a little tedious to find these patients, but it's really critical. Otherwise, you're not going to get reimbursed for these therapies," says Jason Hafron, MD.

"Bladder cancer is exploding. [It] is exciting, it's changing, and we're just at the start of this," says Jason M. Hafron, MD, CMO.

“We then talked a little bit about BCG unresponsive disease, which is a really hot topic,” says Gautam Jayram, MD.

"When we look at focal therapy in general, the better we're able to see, localize, identify and risk stratify prostate cancers, the better we're able to treat them and offer more personalized and focal treatments," says Arvin George, MD.

“We're really excited as robotic surgeons, because this will be the first time in a couple decades that there'll be competition for robots, and that's only going to make things better,” says Ronney Abaza, MD, FACS.

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

"We...talked a little bit about BCG-unresponsive disease, which is a really hot topic; a lot of trials and a lot of data are coming there," says Gautam Jayram, MD.

“The guidelines have changed. They used to be called third-line therapies, and they're no longer quote "third-line" anymore, based on the new guidelines that have come out,” says Kari Bailey, MD.

“You have to be balanced in what to embrace vs what not. It is easy to be wowed by new things," said Scott Eggener, MD.

“Part of the reason that we created this Working Group Session is to essentially highlight the role that APPs can play in building men's health practices,” says Andrew Y. Sun, MD.

“I would say, about 10 years ago, there was a real skepticism, a healthy skepticism, I would say, in the beginning. Now that has slowly changed into optimism,” says Arvin K. George, MD.

“I think that it is upon us as urologists to try to start to embrace this clinical accomplishment, and that being trying to make our patients as stone free as possible,” says Tom Mueller, MD.

“It's exhausting and it's overwhelming, but traction has been gained and continues to be gained and we are making some meaningful, tangible differences,” says Mara R. Holton, MD.

"The Inflation Reduction Act has changed the landscape, and we really still don't understand what those implications are going to be," says Mara R. Holton, MD.

“We have definitely seen significant trends toward transparency in hospital pricing, and in regulations designed to promote that, as well as PBM reform,” says Mara R. Holton, MD.

“This year in particular, we really attempted to highlight a novel conversation about financial toxicity,” says Mara R. Holton, MD.

"This is the 15th year [of LUGPA,] and I think I've gone maybe 12, 13 years in a row or so, almost every year," says Lawrence Gervasi, MD.

"The providers–the nurses and the physicians and the extenders–are checking out and burning out, which is affecting quality and delivery. To me, it's a national health care crisis," says Scott A. MacDiarmid, MD, FRCPSC.

"We are really engaged on ensuring that a lot of the progress that had been made and the care that was delivered through the pandemic is able to continue on," says Joshua Langston, MD.